Shares of Boston Scientific Corporation (NYSE:BSX) have been given an average recommendation of “Buy” by the twenty-one analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $30.91.
A number of equities research analysts recently weighed in on the stock. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday. BMO Capital Markets reiterated a “buy” rating and set a $30.00 price objective on shares of Boston Scientific in a report on Friday, October 13th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, October 3rd. SunTrust Banks reiterated a “buy” rating and set a $34.00 price objective on shares of Boston Scientific in a report on Monday, October 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Monday, September 25th.
In other news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $28.42, for a total value of $440,510.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of Boston Scientific stock in a transaction dated Tuesday, November 28th. The stock was acquired at an average price of $0.45 per share, with a total value of $183,602.70. In the last 90 days, insiders sold 96,585 shares of company stock valued at $2,578,197. Company insiders own 0.74% of the company’s stock.
Boston Scientific (NYSE BSX) traded up $0.06 during trading on Friday, hitting $27.71. 7,970,000 shares of the stock traded hands, compared to its average volume of 9,530,000. The company has a market cap of $38,050.00, a price-to-earnings ratio of 45.43, a PEG ratio of 1.98 and a beta of 0.96. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific has a 12-month low of $23.29 and a 12-month high of $29.93.
Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $0.27 EPS. equities analysts forecast that Boston Scientific will post 1.25 EPS for the current year.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.